Molecular Partners Ag (MOLN) Income from Non-Controlling Interests (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Income from Non-Controlling Interests of $346.07 for Q1 2026, down 85.75% year-over-year from $2429.2 in Q1 2025, and up 174.82% quarter-over-quarter from -$462.54 in Q3 2025.
Molecular Partners Ag (MOLN) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Income from Non-Controlling Interests for 7 consecutive years, with $346.07 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 346.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 346.07 |
| Sep 30, 2025 | -462.54 |
| Jun 30, 2025 | -2,543.82 |
| Mar 31, 2025 | 2,429.16 |
| Sep 30, 2024 | -1,673.60 |
| Jun 30, 2024 | 1,042.76 |
| Mar 31, 2024 | 2,961.59 |
| Sep 30, 2023 | 756.28 |
| Jun 30, 2023 | -1.71 Mn |
| Mar 31, 2023 | 28.11 |
| Sep 30, 2022 | -1,629.81 |
| Jun 30, 2022 | 4.53 Mn |
| Mar 31, 2022 | 2,713.52 |
| Sep 30, 2021 | 2,186.97 |
| Jun 30, 2021 | 7.16 Mn |
| Mar 31, 2021 | 3,598.01 |
| Sep 30, 2020 | -1,800.11 |